Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone Effects on Fibrosis and Portal Pressure
NCT02907749Phase 4Completed
- Start
- Jan 2018
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of spironolactone in Cirrhosis and Portal Hypertension (PH) (2 arms). Primary endpoint: Virtual portal pressure gradient at 6 months. Started Jan 2018; status: completed.
02
Drugs
spironolactone
03
Conditions
CirrhosisPortal Hypertension (PH)
Beyond the preview
Go deeper on NCT02907749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02907749.